GRAIL Reports Third Quarter 2026 Financial Results
FDA Advisory Committee Voted in Favor of Approval of GRAIL’s Galleri Multi- Cancer Early Detection Test
Test Volume Increased ~24% to More Than 56,000 Year-Over-Year, Year-to-Date Test Volume Increased ~36% to More Than 174,000
Q3 Galleri Revenue Grew 14% Year-Over-Year to $37.3 Million SUNNYVALE, Calif. — Nov. 4, 2026 — GRAIL, Inc. (Nasdaq: GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, today reported business and financial results for the third quarter of 2026.
Galleri test revenue for the third quarter grew 14% year-over-year to $37.3 million, and total revenue grew 4% year-over-year to $37.5 million. Galleri test volume for the third quarter grew approximately 24% year-over-year to more than 56,000 tests. Total Galleri test volume and revenue for the nine months ended September 30, 2026 grew 36% year-over-year to more than 174,000 tests and 24% to $119.7 million, respectively. Net loss for the third quarter was $103.6 million. Gross loss was $18.1 million. Non-GAAP adjusted gross profit was $15.9 million, and non-GAAP adjusted EBITDA was $(92.6) million. 1
“GRAIL achieved significant milestones this quarter including a favorable vote for approval of Galleri at the FDA Advisory Committee,” said Josh Ofman, MD, MSHS, Chief Executive Officer of GRAIL. “This achievement strengthens the foundation for Galleri as we continue on our path towards potential regulatory approval, broader access and reimbursement. We are seeing continued commercial momentum as a number of positive advancements, consistent market education, and promotional pricing initiatives gain traction.”
For the three months ended September 30, 2026, as compared to the three months ended September 30, 2025, GRAIL reported:
• Revenue: Total revenue, comprised of screening and development services revenue, was $37.5 million, an increase of $1.3 million or 4%.
: Adjusted EBITDA was $(92.6) million, an increase in adjusted EBITDA loss of $20.9 million or 29%.
• Cash position: Cash, cash equivalents, and short-term marketable securities totaled $788.7 million as of September 30, 2026.
1 See “Non-GAAP Disclosure” and the associated reconciliations for important information about our use of non-GAAP measures.
• Announced a favorable vote for approval of the Galleri test from the FDA's Molecular and Clinical Genetics Panel of the Medical Device Advisory Committee (the “Advisory Committee”) in September. The company anticipates an FDA decision by early Q1 2027.
• Published results from the NHS-Galleri trial in The New England Journal of Medicine and Nature Medicine, and final results from the PATHFINDER 2 study in Nature Medicine. The publications report clinical utility, test performance, and safety results from approximately 175,000 participants enrolled in the UK and North America. The results across the studies demonstrated:
◦ Substantially increased cancer detection (4-6.5x more cancers detected) with robust performance, a favorable safety profile and consistent clinical performance across the two large trials.
◦ Additionally, the NHS-Galleri trial demonstrated a substantial reduction of >20% in Stage IV diagnoses of 12 prespecified aggressive cancers and a 25% reduction in cancers diagnosed after emergency presentation in the Galleri arm compared to the control arm.
◦ In the NHS-Galleri trial, Galleri added to standard-of-care screening detected more Stage I-II cancers than the UK national screening program found all cancers across all stages.
These data support the potential of multi-cancer early detection screening at population scale to identify cancers before symptoms appear — when they can be treated more easily and are potentially curable.
A webcast and conference call will be held today, Nov. 4, 2026, at 1:30 p.m. PT / 4:30 p.m. ET. Individuals interested in listening to the conference call may access it on the investor relations section of GRAIL’s website at investors.grail.com.
GRAIL is a healthcare company whose mission is to detect cancer early, when it can be cured. GRAIL is focused on alleviating the global burden of cancer by using the power of next-generation sequencing, population-scale clinical studies, and state-of-the-art machine learning, software, and automation to detect and identify multiple deadly cancer types in earlier stages. GRAIL’s targeted methylation-based platform can support the continuum of care for screening and precision oncology, including multi-cancer early detection in symptomatic patients, risk stratification, minimal residual disease detection, biomarker subtyping, treatment and recurrence monitoring. GRAIL is headquartered in Sunnyvale, Calif. with locations in Washington, D.C., North Carolina, and the United Kingdom. GRAIL’s common stock is listed under the ticker symbol “GRAL” on the Nasdaq Stock Exchange.
The Galleri multi-cancer early detection test is a proactive tool to screen for cancer. With a simple blood draw, the Galleri test can identify DNA shed by cancer cells, which can act as a unique “fingerprint” of cancer, to help screen for some of the deadliest cancers that don’t have recommended screening today, such as pancreatic, esophageal, ovarian, liver, and others. The Galleri test can be used to screen for cancer before a person becomes symptomatic, when cancer may be more easily treated and potentially curable. The Galleri test can indicate the origin of the cancer, giving healthcare providers a roadmap of where to explore further. The Galleri test requires a prescription from a licensed healthcare provider and should be used in addition to recommended cancer screenings such as mammography, colonoscopy, prostate-specific antigen (PSA) test, or cervical cancer screening. The Galleri test is recommended for adults with an elevated risk for cancer, such as those aged 50 or older.
The GRAIL clinical laboratory is certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA) and accredited by the College of American Pathologists. The Galleri test was developed — and its performance characteristics were determined — by GRAIL. The Galleri test has not been cleared or approved by the Food and Drug Administration. The GRAIL clinical laboratory is regulated under CLIA to perform high-complexity testing. The Galleri test is intended for clinical purposes.
In addition to our financial results provided throughout this press release that are determined in accordance with U.S. generally accepted accounting principles (“GAAP”), this press release also includes financial measures that are not calculated in accordance with GAAP. Our non-GAAP financial disclosure includes Adjusted Gross Profit, Adjusted Gross Margin and Adjusted EBITDA. We encourage investors to carefully consider our results under GAAP in conjunction with our supplemental non-GAAP information and the reconciliation between these presentations.
• Adjusted Gross Profit and Adjusted Gross Margin are key performance measures that our management uses to assess our operational performance, as they represent the results of revenues and direct costs, which are key components of our operations. We believe that these non-GAAP financial measures are useful to investors and other interested parties in analyzing our financial performance because they reflect the gross profitability of our operations, and exclude the costs associated with our sales and marketing, product development, general and administrative activities and the impact of our financing methods and income taxes.
We calculate Adjusted Gross Profit as gross profit (loss) (as defined below) adjusted to exclude amortization of intangible assets and stock-based compensation allocated to cost of revenue. Adjusted Gross Profit should be viewed as a measure of operating performance that is a supplement to, and not a substitute for, operating income or loss from operations, net earnings or loss and other GAAP measures of income (loss) or profitability. Gross profit (loss) (as defined below) is the most directly comparable financial measure calculated in accordance with GAAP. We calculate Adjusted Gross Margin as Adjusted Gross Profit divided by total revenue. 3 • Adjusted EBITDA is a key performance measure that our management uses to assess our financial performance and is also used for internal planning and forecasting purposes. We believe that this non-GAAP financial measure is useful to investors and other interested parties in analyzing our financial performance because it provides a comparable overview of our operations across historical periods. In addition, we believe that providing Adjusted EBITDA, together with a reconciliation of net loss to Adjusted EBITDA, helps investors make comparisons between our company and other companies that may have different capital structures, different tax rates, different operational and ownership histories, and/or different forms of employee compensation.
Adjusted EBITDA is used by our management team as an additional measure of our performance for purposes of business decision-making, including managing expenditures. Period-to-period comparisons of Adjusted EBITDA help our management identify additional trends in our financial results that may not be shown solely by period-to-period comparisons of net income (loss) or income (loss) from operations. Our management recognizes that Adjusted EBITDA has inherent limitations because of the excluded items, and may not be directly comparable to similarly titled metrics used by other companies.
The Company defines Adjusted EBITDA as net loss adjusted for amortization of intangible assets, stock-based compensation, depreciation, intangible and other assets impairment, benefit from income taxes, interest income and restructuring expenses. These adjustments include non-cash items, significant non-recurring charges and/or other non-operating expenses that we do not believe are indicative of ongoing or future business operations.
Adjusted EBITDA should be viewed as a measure of operating performance that is a supplement to, and not a substitute for, operating income or loss from operations, net earnings or loss and other U.S. GAAP measures of income (loss). Additionally, it is not intended to be a measure of free cash flow for management’s discretionary use, as it does not consider certain cash requirements such as interest and tax payments. Further, our definition of Adjusted EBITDA may differ from similarly titled measures used by other companies and therefore may not be comparable among companies. Net loss is the most directly comparable financial measure calculated in accordance with GAAP.
Full reconciliation of these non-GAAP measures to the most comparable GAAP measures is set forth in tabular form following the Condensed Consolidated Balance Sheets and Condensed Consolidated Statements of Operations.
This press release contains forward-looking statements. In some cases, you can identify these statements by forward-looking words such as “aim,” “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “might,” “plan,” “potential,” “predict,” “should,” “would,” or “will,” the negative of these terms, and other comparable terminology. These forward-looking statements, which are subject to risks, uncertainties, and assumptions about us, may include statements related to the potential benefits, uses and impacts of the Galleri test, comparability of clinical study results to a real world setting, benefits of population screening with existing or future versions of Galleri, commercial and expansion plans, growth trends and reimbursement, potential regulatory decision timeline and outcome, and impacts of our commercial strategies, among others. 4 These statements are only predictions based on our current expectations and projections about future events and trends. There are important factors that could cause our actual results, level of activity, performance, or achievements to differ materially and adversely from those expressed or implied by the forward-looking statements, including those factors and numerous associated risks discussed under the sections entitled “Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2025 and our subsequent Quarterly Reports on Form 10-Q. Moreover, we operate in a dynamic and rapidly changing environment. New risks emerge from time to time. It is not possible for our management to predict all risks, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results, level of activity, performance, or achievements to differ materially and adversely from those contained in any forward-looking statements we may make.
Forward-looking statements relate to the future and, accordingly, are subject to inherent uncertainties, risks, and changes in circumstances that are difficult to predict and many of which are outside of our control. Although we believe the expectations and projections expressed or implied by the forward-looking statements are reasonable, we cannot guarantee future results, level of activity, performance, or achievements. Our actual results, financial condition and success in our business strategies and operations may differ materially from those indicated in the forward-looking statements. Except to the extent required by law, we undertake no obligation to update any of these forward-looking statements after the date of this press release to conform our prior statements to actual results or revised expectations or to reflect new information or the occurrence of unanticipated events.
September 30, December 31, 2026 2025 ────────────────────────────────────────────────────────────────────────────── Assets Current assets: Cash and cash equivalents $ 28,976 $ 249,727 Short-term marketable securities 759,700 654,703 Accounts receivable, net 18,998 18,295 Supplies 18,475 16,017 Prepaid expenses and other current 16,649 15,107 assets Total current assets 842,798 953,849 Property and equipment, net 42,691 51,813 Operating lease right-of-use assets 84,073 52,070 Restricted cash 6,943 6,974 Intangible assets, net 1,746,806 1,850,556 Other non-current assets 7,251 6,753 Total assets $ 2,730,562 $ 2,922,015 Liabilities and stockholders’ equity Current liabilities: Accounts payable $ 10,209 $ 2,083 Accrued liabilities 76,305 63,945 Operating lease liabilities, current 6,272 11,715 portion Other current liabilities 1,546 1,927 Total current liabilities 94,332 79,670 Operating lease liabilities, net of 79,576 43,148 current portion Deferred tax liability, net 99,742 218,583 Other non-current liabilities 3,393 2,752 Total liabilities 277,043 344,153 Preferred stock, par value of $0.001 per share; 50,000,000 shares authorized, no — — shares issued and outstanding as of September 30, 2026 and December 31, 2025 Common stock $0.001 par value per share, 1,500,000,000 shares authorized as of September 30, 2026 and December 31, 2025 45 40 and 44,753,179 and 40,331,360 shares issued and outstanding as of September 30, 2026 and December 31, 2025 Additional paid-in capital 12,970,363 12,786,848 Accumulated other comprehensive 1,794 2,655 income Accumulated deficit -10,518,683 -10,211,681 Total stockholders' equity 2,453,519 2,577,862 Total liabilities and stockholders' $ 2,730,562 $ 2,922,015 equity
(1) Gross loss is calculated as total revenue less cost of screening revenue (exclusive of amortization of intangible assets), cost of development services revenue and cost of revenue—amortization of intangible assets.
(2) Adjusted Gross Margin is calculated as adjusted gross profit divided by total revenue. 8
(1) Represents amortization of intangible assets, including developed technology and trade names.
(2) Represents the impairment charge related to the deferred asset recognized in connection with the Samsung SPA in the second quarter of 2026 and the in-process research and development ("IPR&D") impairment charge in the prior period. 9
Full text with the tables
NEWS RELEASE
Exhibit 99.1
GRAIL Reports Third Quarter 2026 Financial Results
FDA Advisory Committee Voted in Favor of Approval of GRAIL’s Galleri Multi-
Cancer Early Detection Test
Q3 Galleri
®
Test Volume Increased ~24% to More Than 56,000 Year-Over-Year, Year-to-Date Test
Volume Increased ~36% to More Than 174,000
Q3 Galleri Revenue Grew 14% Year-Over-Year to $37.3 Million
SUNNYVALE, Calif. — Nov. 4, 2026 — GRAIL, Inc. (Nasdaq: GRAL), a healthcare
company whose mission is to detect cancer early when it can be cured, today
reported business and financial results for the third quarter of 2026.
Galleri test revenue for the third quarter grew 14% year-over-year to $37.3
million, and total revenue grew 4% year-over-year to $37.5 million. Galleri test
volume for the third quarter grew approximately 24% year-over-year to more than
56,000 tests. Total Galleri test volume and revenue for the nine months ended
September 30, 2026 grew 36% year-over-year to more than 174,000 tests and 24% to
$119.7 million, respectively. Net loss for the third quarter was $103.6 million.
Gross loss was $18.1 million. Non-GAAP adjusted gross profit was $15.9 million,
and non-GAAP adjusted EBITDA was $(92.6) million. 1
“GRAIL achieved significant milestones this quarter including a favorable vote
for approval of Galleri at the FDA Advisory Committee,” said Josh Ofman, MD,
MSHS, Chief Executive Officer of GRAIL. “This achievement strengthens the
foundation for Galleri as we continue on our path towards potential regulatory
approval, broader access and reimbursement. We are seeing continued commercial
momentum as a number of positive advancements, consistent market education, and
promotional pricing initiatives gain traction.”
For the three months ended September 30, 2026, as compared to the three months
ended September 30, 2025, GRAIL reported:
• Revenue: Total revenue, comprised of screening and development services
revenue, was $37.5 million, an increase of $1.3 million or 4%.
• Net loss: Net loss was $103.6 million, an increase of $14.6 million or 16%.
• Gross loss: Gross loss was $18.1 million, an increase of $4.4 million or 32%.
•
Adjusted gross profit
1
: Adjusted gross profit was $15.9 million, a decrease of $4.1 million or 20%.
•
Adjusted EBITDA
1
: Adjusted EBITDA was $(92.6) million, an increase in adjusted EBITDA loss of
$20.9 million or 29%.
• Cash position: Cash, cash equivalents, and short-term marketable securities
totaled $788.7 million as of September 30, 2026.
1 See “Non-GAAP Disclosure” and the associated reconciliations for important
information about our use of non-GAAP measures.
Recent business highlights include:
• Announced a favorable vote for approval of the Galleri test from the FDA's
Molecular and Clinical Genetics Panel of the Medical Device Advisory Committee
(the “Advisory Committee”) in September. The company anticipates an FDA decision
by early Q1 2027.
• Published results from the NHS-Galleri trial in The New England Journal of
Medicine and Nature Medicine, and final results from the PATHFINDER 2 study in
Nature Medicine. The publications report clinical utility, test performance, and
safety results from approximately 175,000 participants enrolled in the UK and
North America. The results across the studies demonstrated:
◦ Substantially increased cancer detection (4-6.5x more cancers detected) with
robust performance, a favorable safety profile and consistent clinical
performance across the two large trials.
◦ Additionally, the NHS-Galleri trial demonstrated a substantial reduction of
>20% in Stage IV diagnoses of 12 prespecified aggressive cancers and a 25%
reduction in cancers diagnosed after emergency presentation in the Galleri arm
compared to the control arm.
◦ In the NHS-Galleri trial, Galleri added to standard-of-care screening detected
more Stage I-II cancers than the UK national screening program found all cancers
across all stages.
These data support the potential of multi-cancer early detection screening at
population scale to identify cancers before symptoms appear — when they can be
treated more easily and are potentially curable.
Conference Call and Webcast
A webcast and conference call will be held today, Nov. 4, 2026, at 1:30 p.m. PT
/ 4:30 p.m. ET. Individuals interested in listening to the conference call may
access it on the investor relations section of GRAIL’s website at
investors.grail.com.
A replay of the webcast will be available on GRAIL’s website for 30 days.
About GRAIL
GRAIL is a healthcare company whose mission is to detect cancer early, when it
can be cured. GRAIL is focused on alleviating the global burden of cancer by
using the power of next-generation sequencing, population-scale clinical
studies, and state-of-the-art machine learning, software, and automation to
detect and identify multiple deadly cancer types in earlier stages. GRAIL’s
targeted methylation-based platform can support the continuum of care for
screening and precision oncology, including multi-cancer early detection in
symptomatic patients, risk stratification, minimal residual disease detection,
biomarker subtyping, treatment and recurrence monitoring. GRAIL is headquartered
in Sunnyvale, Calif. with locations in Washington, D.C., North Carolina, and the
United Kingdom. GRAIL’s common stock is listed under the ticker symbol “GRAL” on
the Nasdaq Stock Exchange.
For more information, visit grail.com .
2
About Galleri®
The Galleri multi-cancer early detection test is a proactive tool to screen for
cancer. With a simple blood draw, the Galleri test can identify DNA shed by
cancer cells, which can act as a unique “fingerprint” of cancer, to help screen
for some of the deadliest cancers that don’t have recommended screening today,
such as pancreatic, esophageal, ovarian, liver, and others. The Galleri test can
be used to screen for cancer before a person becomes symptomatic, when cancer
may be more easily treated and potentially curable. The Galleri test can
indicate the origin of the cancer, giving healthcare providers a roadmap of
where to explore further. The Galleri test requires a prescription from a
licensed healthcare provider and should be used in addition to recommended
cancer screenings such as mammography, colonoscopy, prostate-specific antigen
(PSA) test, or cervical cancer screening. The Galleri test is recommended for
adults with an elevated risk for cancer, such as those aged 50 or older.
For more information, visit galleri.com .
Laboratory/Test Information
The GRAIL clinical laboratory is certified under the Clinical Laboratory
Improvement Amendments of 1988 (CLIA) and accredited by the College of American
Pathologists. The Galleri test was developed — and its performance
characteristics were determined — by GRAIL. The Galleri test has not been
cleared or approved by the Food and Drug Administration. The GRAIL clinical
laboratory is regulated under CLIA to perform high-complexity testing. The
Galleri test is intended for clinical purposes.
Non-GAAP Disclosure
In addition to our financial results provided throughout this press release that
are determined in accordance with U.S. generally accepted accounting principles
(“GAAP”), this press release also includes financial measures that are not
calculated in accordance with GAAP. Our non-GAAP financial disclosure includes
Adjusted Gross Profit, Adjusted Gross Margin and Adjusted EBITDA. We encourage
investors to carefully consider our results under GAAP in conjunction with our
supplemental non-GAAP information and the reconciliation between these
presentations.
• Adjusted Gross Profit and Adjusted Gross Margin are key performance measures
that our management uses to assess our operational performance, as they
represent the results of revenues and direct costs, which are key components of
our operations. We believe that these non-GAAP financial measures are useful to
investors and other interested parties in analyzing our financial performance
because they reflect the gross profitability of our operations, and exclude the
costs associated with our sales and marketing, product development, general and
administrative activities and the impact of our financing methods and income
taxes.
We calculate Adjusted Gross Profit as gross profit (loss) (as defined below)
adjusted to exclude amortization of intangible assets and stock-based
compensation allocated to cost of revenue. Adjusted Gross Profit should be
viewed as a measure of operating performance that is a supplement to, and not a
substitute for, operating income or loss from operations, net earnings or loss
and other GAAP measures of income (loss) or profitability. Gross profit (loss)
(as defined below) is the most directly comparable financial measure calculated
in accordance with GAAP. We calculate Adjusted Gross Margin as Adjusted Gross
Profit divided by total revenue.
3
• Adjusted EBITDA is a key performance measure that our management uses to
assess our financial performance and is also used for internal planning and
forecasting purposes. We believe that this non-GAAP financial measure is useful
to investors and other interested parties in analyzing our financial performance
because it provides a comparable overview of our operations across historical
periods. In addition, we believe that providing Adjusted EBITDA, together with a
reconciliation of net loss to Adjusted EBITDA, helps investors make comparisons
between our company and other companies that may have different capital
structures, different tax rates, different operational and ownership histories,
and/or different forms of employee compensation.
Adjusted EBITDA is used by our management team as an additional measure of our
performance for purposes of business decision-making, including managing
expenditures. Period-to-period comparisons of Adjusted EBITDA help our
management identify additional trends in our financial results that may not be
shown solely by period-to-period comparisons of net income (loss) or income
(loss) from operations. Our management recognizes that Adjusted EBITDA has
inherent limitations because of the excluded items, and may not be directly
comparable to similarly titled metrics used by other companies.
The Company defines Adjusted EBITDA as net loss adjusted for amortization of
intangible assets, stock-based compensation, depreciation, intangible and other
assets impairment, benefit from income taxes, interest income and restructuring
expenses. These adjustments include non-cash items, significant non-recurring
charges and/or other non-operating expenses that we do not believe are
indicative of ongoing or future business operations.
Adjusted EBITDA should be viewed as a measure of operating performance that is a
supplement to, and not a substitute for, operating income or loss from
operations, net earnings or loss and other U.S. GAAP measures of income (loss).
Additionally, it is not intended to be a measure of free cash flow for
management’s discretionary use, as it does not consider certain cash
requirements such as interest and tax payments. Further, our definition of
Adjusted EBITDA may differ from similarly titled measures used by other
companies and therefore may not be comparable among companies. Net loss is the
most directly comparable financial measure calculated in accordance with GAAP.
Full reconciliation of these non-GAAP measures to the most comparable GAAP
measures is set forth in tabular form following the Condensed Consolidated
Balance Sheets and Condensed Consolidated Statements of Operations.
Forward-Looking Statements
This press release contains forward-looking statements. In some cases, you can
identify these statements by forward-looking words such as “aim,” “anticipate,”
“believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “might,”
“plan,” “potential,” “predict,” “should,” “would,” or “will,” the negative of
these terms, and other comparable terminology. These forward-looking statements,
which are subject to risks, uncertainties, and assumptions about us, may include
statements related to the potential benefits, uses and impacts of the Galleri
test, comparability of clinical study results to a real world setting, benefits
of population screening with existing or future versions of Galleri, commercial
and expansion plans, growth trends and reimbursement, potential regulatory
decision timeline and outcome, and impacts of our commercial strategies, among
others.
4
These statements are only predictions based on our current expectations and
projections about future events and trends. There are important factors that
could cause our actual results, level of activity, performance, or achievements
to differ materially and adversely from those expressed or implied by the
forward-looking statements, including those factors and numerous associated
risks discussed under the sections entitled “Risk Factors” in our Annual Report
on Form 10-K for the year ended December 31, 2025 and our subsequent Quarterly
Reports on Form 10-Q. Moreover, we operate in a dynamic and rapidly changing
environment. New risks emerge from time to time. It is not possible for our
management to predict all risks, nor can we assess the impact of all factors on
our business or the extent to which any factor, or combination of factors, may
cause actual results, level of activity, performance, or achievements to differ
materially and adversely from those contained in any forward-looking statements
we may make.
Forward-looking statements relate to the future and, accordingly, are subject to
inherent uncertainties, risks, and changes in circumstances that are difficult
to predict and many of which are outside of our control. Although we believe the
expectations and projections expressed or implied by the forward-looking
statements are reasonable, we cannot guarantee future results, level of
activity, performance, or achievements. Our actual results, financial condition
and success in our business strategies and operations may differ materially from
those indicated in the forward-looking statements. Except to the extent required
by law, we undertake no obligation to update any of these forward-looking
statements after the date of this press release to conform our prior statements
to actual results or revised expectations or to reflect new information or the
occurrence of unanticipated events.
GRAIL Contacts
Corporate Communications
Kristen Davis
Trish Rowland
[email protected]
Investor Relations
Alex Dobbin
Alexis Tosti
[email protected]
5
GRAIL, Inc.
Condensed Consolidated Balance Sheets
(unaudited)
(amounts in thousands, except share and per share data)
September 30, December 31,
2026 2025
──────────────────────────────────────────────────────────────────────────────
Assets
Current assets:
Cash and cash equivalents $ 28,976 $ 249,727
Short-term marketable securities 759,700 654,703
Accounts receivable, net 18,998 18,295
Supplies 18,475 16,017
Prepaid expenses and other current 16,649 15,107
assets
Total current assets 842,798 953,849
Property and equipment, net 42,691 51,813
Operating lease right-of-use assets 84,073 52,070
Restricted cash 6,943 6,974
Intangible assets, net 1,746,806 1,850,556
Other non-current assets 7,251 6,753
Total assets $ 2,730,562 $ 2,922,015
Liabilities and stockholders’ equity
Current liabilities:
Accounts payable $ 10,209 $ 2,083
Accrued liabilities 76,305 63,945
Operating lease liabilities, current 6,272 11,715
portion
Other current liabilities 1,546 1,927
Total current liabilities 94,332 79,670
Operating lease liabilities, net of 79,576 43,148
current portion
Deferred tax liability, net 99,742 218,583
Other non-current liabilities 3,393 2,752
Total liabilities 277,043 344,153
Preferred stock, par value of $0.001
per
share; 50,000,000 shares authorized,
no — —
shares issued and outstanding as of
September 30, 2026 and December 31,
2025
Common stock $0.001 par value per
share,
1,500,000,000 shares authorized as of
September 30, 2026 and December 31,
2025 45 40
and 44,753,179 and 40,331,360 shares
issued and outstanding as of
September
30, 2026 and December 31, 2025
Additional paid-in capital 12,970,363 12,786,848
Accumulated other comprehensive 1,794 2,655
income
Accumulated deficit -10,518,683 -10,211,681
Total stockholders' equity 2,453,519 2,577,862
Total liabilities and stockholders' $ 2,730,562 $ 2,922,015
equity
6
GRAIL, Inc.
Condensed Consolidated Statements of Operations
(unaudited)
(amounts in thousands, except share and per share data)
Three Septem… Septem… Nine Septem… Septemb…
Months 30, 30, Months 30, 30,
Ended 2026 2025 Ended 2026 2025
──────────────────────────────────────────────────────────────────────────────
Reven…
Scree… $ 37,269 $ 32,807 $ 119,743 $ 96,319
reven…
Devel…
servi… 266 3,387 3,264 7,256
reven…
Total 37,535 36,194 123,007 103,575
reven…
Costs
and
opera…
expen…
Cost
of
scree…
reven…
(excl… 22,032 15,910 66,623 52,379
of
amort…
of
intan…
asset…
Cost
of
devel… 141 544 951 2,216
servi…
reven…
Cost
of
reven…
— 33,473 33,473 100,417 100,417
amort…
of
intan…
assets
Resea…
and 44,073 48,647 139,523 148,898
devel…
Sales
and 41,695 25,503 110,020 89,021
marke…
Gener…
and 40,740 37,408 134,217 120,396
admin…
Intan…
and
other — — 25,423 28,000
assets
impai…
Total
costs
and 182,154 161,485 577,174 541,327
opera…
expen…
Loss
from -144,6… -125,2… -454,1… -437,752
opera…
Other
incom…
Inter… 7,843 6,107 23,059 20,695
income
Other
income -545 466 -444 -929
(expe…
net
Total
other 7,298 6,573 22,615 19,766
incom…
net
Loss
before -137,3… -118,7… -431,5… -417,986
income
taxes
Benef…
from 33,753 29,741 124,550 108,811
income
taxes
Net $ -103,5… $ -88,977 $ -307,0… $ -309,175
loss
Net
loss
per
share $ -2.21 $ -2.46 $ -6.84 $ -8.73
—
Basic
and
Dilut…
Weigh…
shares
of
common
stock
used 46,777… 36,124… 44,858… 35,415,…
in
compu…
net
loss
per
share:
7
GRAIL, Inc.
Reconciliation of GAAP to Non-GAAP Financial Measures
(unaudited)
(amounts in thousands)
Three Nine
Mont… Mont…
Ended Ended
Sept… Sept… Sept… Sept…
30, 30, 30, 30,
2026 2025 2026 2025
──────────────────────────────────────────────────────────────────────────────
Gro… $ -18,… $ -13,… $ -44,… $ -51,…
los…
Amo…
of 33,4… 33,4… 100,… 100,…
int…
ass…
Sto… 552 271 1,734 1,450
com…
Adj…
Gro… $ 15,9… $ 20,0… $ 57,1… $ 50,4…
Pro…
Adj…
Gro… 42% 55% 46% 49%
Mar…
(1) Gross loss is calculated as total revenue less cost of screening revenue
(exclusive of amortization of intangible assets), cost of development services
revenue and cost of revenue—amortization of intangible assets.
(2) Adjusted Gross Margin is calculated as adjusted gross profit divided by
total revenue.
8
GRAIL, Inc.
Reconciliation of GAAP to Non-GAAP Financial Measures
(unaudited)
(amounts in thousands)
Three Septem… Septem… Nine Septem… Septemb…
Months 30, 30, Months 30, 30,
Ended 2026 2025 Ended 2026 2025
──────────────────────────────────────────────────────────────────────────────
Net $ -103,5… $ -88,977 $ -307,0… $ -309,175
loss
Adjus…
to
exclu…
the
follo…
Amort…
of 34,583 34,583 103,750 103,750
intan…
asset…
Stock… 14,109 14,139 50,459 44,518
compe…
Intan…
and
other — — 25,423 28,000
assets
impai…
Depre… 3,892 4,399 12,207 13,686
Benef…
from -33,753 -29,741 -124,5… -108,811
income
taxes
Inter… -7,843 -6,107 -23,059 -20,695
income
Restr… — — — -34
Adjus… $ -92,580 $ -71,704 $ -262,7… $ -248,761
EBITDA
(1) Represents amortization of intangible assets, including developed technology
and trade names.
(2) Represents the impairment charge related to the deferred asset recognized in
connection with the Samsung SPA in the second quarter of 2026 and the in-process
research and development ("IPR&D") impairment charge in the prior period.
9